These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D'Eril GV, Moratti R, Merlini G. Clin Chem; 2009 Mar 22; 55(3):499-504. PubMed ID: 19131635 [Abstract] [Full Text] [Related]
10. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Kaplan B, Ramirez-Alvarado M, Sikkink L, Golderman S, Dispenzieri A, Livneh A, Gallo G. Br J Haematol; 2009 Mar 22; 144(5):705-15. PubMed ID: 19076171 [Abstract] [Full Text] [Related]
11. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis. Bomsztyk J, Ravichandran S, Giles HV, Wright N, Berlanga O, Khwaja J, Mahmood S, Wisniowski B, Cohen O, Foard D, Gilbertson J, Rauf MU, Starr N, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore JD, Lachmann H, Harding S, Pratt G, Wechalekar AD. Blood; 2024 Mar 28; 143(13):1259-1268. PubMed ID: 38194690 [Abstract] [Full Text] [Related]